Safety and Immunogenicity of a Human Papillomavirus Peptide Vaccine (CIGB-228) in Women with High-Grade Cervical Intraepithelial Neoplasia: First-in-Human, Proof-of-Concept Trial

Table 4

IFNγ ELISPOT analysis of PBMC before and after vaccinations of patients.

		Patients
		01	02	03	04	05	06	07
Prevaccination	86–93	315	100	70	180	100	160	90
	82–90	265	30	80	145	90	90	50
	11–20	300	15	80	120	50	75	50
	M1	85	85	60	75	50	85	60
After one vaccination	86–93	425	145	190	190	110	175	110
	82–90	260	45	150	150	100	115	60
	11–20	315	25	130	130	75	110	60
	M1	90	90	75	75	45	90	55
After two vaccinations	86–93	540	305	125	530	320	460	220
	82–90	435	185	85	360	220	420	100
	11–20	335	115	115	315	230	425	105
	M1	80	80	55	80	50	80	55
After three vaccinations	86–93	670	285	190	425	215	510	245
	82–90	710	160	150	320	190	445	160
	11–20	595	100	180	290	155	480	140
	M1	80	80	55	60	55	80	55
After four vaccinations	86–93	655	195	275	450	190	450	200
	82–90	725	140	160	335	180	375	110
	11–20	550	105	165	300	130	410	85
	M1	75	75	60	80	50	75	60

Note: The PBMCs were tested against three peptide of HPV16 E7 (86–93, 82–90 and 11–20). M1 was taken as positive control. In bold, the positive responses (definition is described in Section 2) are depicted as number of specific spots per 10⁶ PBMCs.